Chemistry:5F-AB-FUPPYCA
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C20H26F2N4O2 |
| Molar mass | 392.451 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
5F-AB-FUPPYCA (also known as AZ-037) is a pyrazole-based synthetic cannabinoid that is presumed to be an agonist of the CB1 receptor and has been sold online as a designer drug.[1][2] It was first detected by the EMCDDA as part of a seizure of 540 g white powder in France in February 2015.[3]
The name AZ-037 is also used as a synonym for its structural isomer 5-fluoro-3,5-AB-PFUPPYCA.[4] Thus AZ-037 is being used as a synonym for two different compounds.
5-fluoro-3,5-AB-PFUPPYCA has been detected in synthetic cannabinoid smoke blends in the USA as early as December 30, 2021, along with ADB-BUTINACA, MDA-19 (BZO-HEXOXIZID) and MDMB-4en-PINACA.[5]
5-fluoro-AB-PFUPPYCA contains some similar structural elements to other synthetic cannabinoids such as AB-CHFUPYCA, JWH-307, JWH-030, JWH-147, AB-PINACA. It may be considered an analog of the traditional pyrazole cannabinoid receptor 1 antagonist rimonabant. The pharmacological properties of 5F-AB-FUPPYCA have not been studied.
Legality
In the United States, 5F-AB-FUPPYCA is unscheduled at the federal level as of May 22, 2023. It's possible that it may be considered under the federal analogue act as a functional analog due to pharmacology or as a distant structural analog of JWH-307.
North Dakota has placed 5F-AB-FUPPYCA (N-(1-carbamoyl-2-methyl-propyl)-2-(5-fluoropentyl)-5-(4-fluorophenyl)pyrazole-3-carboxamide) into Schedule I status on 04/27/2023. However, this did not include structural substitutions it gave to other cannabinoid structural classes. As such does not include other pyrazoles analogs such as the non-fluorinated AB-FUPPYCA analog.[6]
See also
- AB-CHFUPYCA
- AM-6545
- TM-38837
- Rimonabant
- JWH-307
- JWH-147
- JWH-030
- AB-FUBINACA
- ADB-FUBINACA
- AMB-FUBINACA
- APP-FUBINACA
- MDA-19
- FUB-144
- FUB-APINACA
- FUB-JWH-018
- FDU-PB-22
- FUB-PB-22
- MDMB-FUBICA
- MDMB-FUBINACA
References
- ↑ "Structure elucidation of the designer drug N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-3-(4-fluorophenyl)-pyrazole-5-carboxamide and the relevance of predicted (13) C NMR shifts - a case study". Drug Testing and Analysis 8 (7): 668–75. July 2016. doi:10.1002/dta.1820. PMID 26012418.
- ↑ "Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues". ACS Chemical Neuroscience 7 (9): 1241–54. September 2016. doi:10.1021/acschemneuro.6b00137. PMID 27421060.
- ↑ "2015. ÉVI EURÓPAI KÁBÍTÓSZER - JELENTÉS - A MONITOROZÁS 20 ÉVE". Hungarian National Focal Point (NFP). June 2015. http://drogfokuszpont.hu/wp-content/uploads/NFP_hirlevel_2015_junius.pdf.
- ↑ "5-fluoro-3,5-AB-PFUPPYCA". Cayman Chemical Company. https://www.caymanchem.com/product/17181.
- ↑ "Test Details : Result #11908 - Plant Material, 11908". DrugsData.org (was EcstasyData). https://drugsdata.org/view.php?id=11908.
- ↑ "AN ACT to amend and reenact sections 19-03.1-05, 19-03.1-11, and 19-03.1-13 of the North Dakota Century Code, relating to the scheduling of controlled substances; and to declare an emergency.". Sixty-eighth Legislative Assembly of North Dakota in Regular Session. 3 January 2023. https://www.ndlegis.gov/prod/assembly/68-2023/regular/documents/23-8099-04000.pdf.
 |  |
